Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16460607 | 0.85 | NPC1 (0.55) | HTTHRH3NPC1RAB9ANPSR1 | |
| SCHEMBL3534460 | 0.84 | HRH3 (0.54) | HTTHRH3NPC1RAB9ANPSR1 | |
| SCHEMBL16460590 | 0.81 | HRH3 (0.62) | HTTHRH3NPC1RAB9ANPSR1 | |
| SCHEMBL3533594 | 0.79 | HRH3 (0.48) | HTTHRH3NPC1RAB9ANPSR1 | |
| SCHEMBL3532487 | 0.76 | HRH3 (0.57) | HTTHRH3NPC1RAB9AALDH1A1 | |
| SCHEMBL3535932 | 0.76 | HRH3 (0.73) | HTTHRH3NPC1RAB9ANPSR1 | |
| SCHEMBL3533694 | 0.76 | HRH3 (0.73) | HTTHRH3NPC1RAB9ANPSR1 | |
| SCHEMBL3532776 | 0.75 | NPC1 (0.48) | HTTHRH3NPC1RAB9AALDH1A1 | |
| SCHEMBL3534218 | 0.75 | NPSR1 (0.48) | HTTHRH3NPC1RAB9ANPSR1 | |
| SCHEMBL3534692 | 0.75 | HRH3 (0.79) | HTTHRH3NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909193-B1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-19 | — | — | EP | disclosed |
| US-9309222-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-12 | — | — | US | disclosed |
| US-9309222-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-12 | — | — | US | disclosed |
| US-9309222-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-12 | — | — | US | disclosed |
| EP-2909193-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014062667-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-24 | — | — | WO | disclosed |
| US-20140107097-A1 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-17 | — | — | US | disclosed |
| US-20140107097-A1 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-17 | — | — | US | disclosed |
| US-20140107097-A1 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-17 | — | — | US | disclosed |
| US-7807837-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| US-20090143591-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143591-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-04 | — | — | US | disclosed |
| EP-1747203-A4 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-7507756-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-24 | — | — | US | disclosed |
| US-7507756-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-24 | — | — | US | disclosed |
| US-7507756-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-24 | — | — | US | disclosed |
| CN-1980896-A | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | CN | disclosed |
| EP-1747203-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005110998-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143591-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | ABL1, NOS2, FLT3 | HTT 2229/4885HRH3 2308/4885NPC1 2095/4885 |
| US-20140107097-A1 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | HTT 2057/4885HRH3 70/4885NPC1 2743/4885 |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | ABL1, NOS2, FLT3 | HTT 2229/4885HRH3 2308/4885NPC1 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.